Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

370 ARTÍCULOS , VIENDO DEL 166 AL 180

Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design

Devanand DP, Strickler JG, Huey ED, Crocco E, Forester BP, Husain MM, Vahia IV, Andrews H, Wall MM, Pelton GH.

Contemp Clin Trials. 2018 Aug;71:33-39. doi: 10.1016/j.cct.2018.05.019. Epub 2018 May 31.

A New Perspective in Utilizing MMP-9 as a Therapeutic Target for Alzheimer's Disease and Type 2 Diabetes Mellitus

Kaminari A, Tsilibary EC, Tzinia A.

J Alzheimers Dis. 2018;64(1):1-16. doi: 10.3233/JAD-180035.

Machine Learning-based Virtual Screening and Its Applications to Alzheimer's Drug Discovery: A Review

Carpenter KA, Huang X.

Curr Pharm Des. 2018;24(28):3347-3358. doi: 10.2174/1381612824666180607124038.

Reactive Astrocytes as Drug Target in Alzheimer's Disease

Assefa BT, Gebre AK, Altaye BM.

Biomed Res Int. 2018 May 14;2018:4160247. doi: 10.1155/2018/4160247. eCollection 2018.

Multi-targetable chalcone analogs to treat deadly Alzheimer's disease: Current view and upcoming advice

Zhang X, Rakesh KP, Bukhari SNA, Balakrishna M, Manukumar HM, Qin HL.

Bioorg Chem. 2018 Oct;80:86-93. doi: 10.1016/j.bioorg.2018.06.009. Epub 2018 Jun 5.

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors

Giacobini E, Pepeu G.

Curr Alzheimer Res. 2018;15(11):1077-1084. doi: 10.2174/1567205015666180613111504.

Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents

Blesa R, Toriyama K, Ueda K, Knox S, Grossberg G.

Curr Alzheimer Res. 2018;15(10):964-974. doi: 10.2174/1567205015666180613112040.

Tau-targeting therapies for Alzheimer disease

Congdon EE, Sigurdsson EM.

Nat Rev Neurol. 2018 Jul;14(7):399-415. doi: 10.1038/s41582-018-0013-z.

Precision medicine and drug development in Alzheimer's disease: the importance of sexual dimorphism and patient stratification

Hampel H, Vergallo A, Giorgi FS, Kim SH, Depypere H, Graziani M, Saidi A, Nisticò R, Lista S; Alzheimer Precision Medicine Initiative (APMI).

Front Neuroendocrinol. 2018 Jul;50:31-51. doi: 10.1016/j.yfrne.2018.06.001. Epub 2018 Jun 12.

Understanding the impact of sex and gender in Alzheimer's disease: A call to action

Nebel RA, Aggarwal NT, Barnes LL, Gallagher A, Goldstein JM, Kantarci K, Mallampalli MP, Mormino EC, Scott L, Yu WH, Maki PM, Mielke MM.

Alzheimers Dement. 2018 Sep;14(9):1171-1183. doi: 10.1016/j.jalz.2018.04.008. Epub 2018 Jun 12.

Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study

Salloway SP, Sperling R, Fox NC, Sabbagh MN, Honig LS, Porsteinsson AP, Rofael H, Ketter N, Wang D, Liu E, Carr S, Black RS, Brashear HR.

J Alzheimers Dis. 2018;64(3):689-707. doi: 10.3233/JAD-171157.

Donepezil for dementia due to Alzheimer's disease

Birks JS, Harvey RJ.

Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3.

Novel multi-target directed ligand-based strategies for reducing neuroinflammation in Alzheimer's disease

Wenzel TJ, Klegeris A.

Life Sci. 2018 Aug 15;207:314-322. doi: 10.1016/j.lfs.2018.06.025. Epub 2018 Jun 22.

Nutritional Intervention to Prevent Alzheimer's Disease: Potential Benefits of Xanthophyll Carotenoids and Omega-3 Fatty Acids Combined

Nolan JM, Mulcahy R, Power R, Moran R, Howard AN.

J Alzheimers Dis. 2018;64(2):367-378. doi: 10.3233/JAD-180160.

Consequences of Pharmacological BACE Inhibition on Synaptic Structure and Function

Zhu K, Peters F, Filser S, Herms J.

Biol Psychiatry. 2018 Oct 1;84(7):478-487. doi: 10.1016/j.biopsych.2018.04.022. Epub 2018 Jun 23.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias